These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 19941668)
21. Using Latent Class Analysis to Model Preference Heterogeneity in Health: A Systematic Review. Zhou M; Thayer WM; Bridges JFP Pharmacoeconomics; 2018 Feb; 36(2):175-187. PubMed ID: 28975582 [TBL] [Abstract][Full Text] [Related]
22. Symptom and function profiles of men with localized prostate cancer. Reeve BB; Tan X; Chen RC; Usinger DS; Pinheiro LC Cancer; 2018 Jul; 124(13):2832-2840. PubMed ID: 29660795 [TBL] [Abstract][Full Text] [Related]
23. Robust Health Utility Assessment Among Long-term Survivors of Prostate Cancer: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor Registry. Jeong CW; Cowan JE; Broering JM; Ten Ham RMT; Wilson LS; Carroll PR; Cooperberg MR Eur Urol; 2019 Dec; 76(6):743-751. PubMed ID: 31345635 [TBL] [Abstract][Full Text] [Related]
24. Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment. Menges D; Piatti MC; Omlin A; Cathomas R; Benamran D; Fischer S; Iselin C; Küng M; Lorch A; Prause L; Rothermundt C; O'Meara Stern A; Zihler D; Lippuner M; Braun J; Cerny T; Puhan MA Eur Urol Open Sci; 2023 May; 51():26-38. PubMed ID: 37187724 [TBL] [Abstract][Full Text] [Related]
25. A review of measurement of patient preferences for treatment outcomes after prostate cancer. Lubeck DP; Grossfeld GD; Carroll PR Urology; 2002 Sep; 60(3 Suppl 1):72-7; discussion 77-8. PubMed ID: 12231054 [TBL] [Abstract][Full Text] [Related]
26. Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment. Sculpher M; Bryan S; Fry P; de Winter P; Payne H; Emberton M BMJ; 2004 Feb; 328(7436):382. PubMed ID: 14751919 [TBL] [Abstract][Full Text] [Related]
27. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow. Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849 [TBL] [Abstract][Full Text] [Related]
28. Interactions between lower urinary tract symptoms and cardiovascular risk factors determine distinct patterns of erectile dysfunction: a latent class analysis. Barbosa JA; Muracca E; Nakano É; Assalin AR; Cordeiro P; Paranhos M; Cury J; Srougi M; Antunes AA J Urol; 2013 Dec; 190(6):2177-82. PubMed ID: 23727187 [TBL] [Abstract][Full Text] [Related]
29. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions. Loeb S; Zhou Q; Siebert U; Rochau U; Jahn B; Mühlberger N; Carter HB; Lepor H; Braithwaite RS Eur Urol; 2017 Dec; 72(6):899-907. PubMed ID: 28844371 [TBL] [Abstract][Full Text] [Related]
30. Heterogeneity in Quality of Life of Long-Term Colon Cancer Survivors: A Latent Class Analysis of the Population-Based PROFILES Registry. Clouth FJ; Moncada-Torres A; Geleijnse G; Mols F; van Erning FN; de Hingh IHJT; Pauws SC; van de Poll-Franse LV; Vermunt JK Oncologist; 2021 Mar; 26(3):e492-e499. PubMed ID: 33355968 [TBL] [Abstract][Full Text] [Related]
31. Agreement between prostate cancer patients and their clinicians about utilities and attribute importance. Elstein AS; Chapman GB; Chmiel JS; Knight SJ; Chan C; Nadler RB; Kuzel TM; Siston AK; Bennett CL Health Expect; 2004 Jun; 7(2):115-25. PubMed ID: 15117386 [TBL] [Abstract][Full Text] [Related]
32. Perception of cancer and inconsistency in medical information are associated with decisional conflict: a pilot study of men with prostate cancer who undergo active surveillance. Goh AC; Kowalkowski MA; Bailey DE; Kazer MW; Knight SJ; Latini DM BJU Int; 2012 Jul; 110(2 Pt 2):E50-6. PubMed ID: 22145791 [TBL] [Abstract][Full Text] [Related]
34. Pilot study of a utilities-based treatment decision intervention for prostate cancer patients. Knight SJ; Nathan DP; Siston AK; Kattan MW; Elstein AS; Collela KM; Wolf MS; Slimack NS; Bennett CL; Golub RM Clin Prostate Cancer; 2002 Sep; 1(2):105-14. PubMed ID: 15046701 [TBL] [Abstract][Full Text] [Related]
35. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Qaseem A; Barry MJ; Denberg TD; Owens DK; Shekelle P; Ann Intern Med; 2013 May; 158(10):761-769. PubMed ID: 23567643 [TBL] [Abstract][Full Text] [Related]
36. Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer. Taylor KL; Hoffman RM; Davis KM; Luta G; Leimpeter A; Lobo T; Kelly SP; Shan J; Aaronson D; Tomko CA; Starosta AJ; Hagerman CJ; Van Den Eeden SK Cancer Epidemiol Biomarkers Prev; 2016 Aug; 25(8):1240-50. PubMed ID: 27257092 [TBL] [Abstract][Full Text] [Related]
37. A psychometric analysis of the measurement level of the rating scale, time trade-off, and standard gamble. Cook KF; Ashton CM; Byrne MM; Brody B; Geraci J; Giesler RB; Hanita M; Souchek J; Wray NP Soc Sci Med; 2001 Nov; 53(10):1275-85. PubMed ID: 11676400 [TBL] [Abstract][Full Text] [Related]
38. Preferences of husbands and wives for outcomes of prostate cancer screening and treatment. Volk RJ; Cantor SB; Cass AR; Spann SJ; Weller SC; Krahn MD J Gen Intern Med; 2004 Apr; 19(4):339-48. PubMed ID: 15061743 [TBL] [Abstract][Full Text] [Related]
39. Prostate cancer screening: a decision analysis. Cantor SB; Spann SJ; Volk RJ; Cardenas MP; Warren MM J Fam Pract; 1995 Jul; 41(1):33-41. PubMed ID: 7798064 [TBL] [Abstract][Full Text] [Related]